BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/14/2026 9:17:09 AM | Browse: 5 | Download: 31
 |
Received |
|
2025-12-02 09:39 |
|
Peer-Review Started |
|
2025-12-02 09:39 |
|
First Decision by Editorial Office Director |
|
2025-12-18 09:08 |
|
Return for Revision |
|
2025-12-18 09:08 |
|
Revised |
|
2025-12-29 11:56 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-02-06 02:50 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-02-06 11:02 |
|
Articles in Press |
|
2026-02-06 11:02 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-04-28 00:15 |
|
Publish the Manuscript Online |
|
2026-05-14 09:17 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Impact of sintilimab with first-line therapy on tumor marker response in advanced gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong-Liang Quan, Lin Xia, Yan Hu, Gui-Yuan Wang and Chao Wang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| 2024 Hefei BOE Hospital Institutional Research Project |
No. YJKT2024008 |
| Anhui Provincial Higher Education Scientific Research Project (Natural Science Category) |
No. 2024AH050672 |
|
| Corresponding Author |
Chao Wang, Chief Physician, Department of Oncology, The Fourth Affiliated Hospital of Anhui Medical University, No. 64 Chaohu North Road, Hefei 238000, Anhui Province, China. wangchao10107@163.com |
| Key Words |
Sintilimab; S-1 plus oxaliplatin regimen; Capecitabine plus oxaliplatin regimen; Advanced gastric cancer; Tumor markers; Carcinoembryonic antigen; Carbohydrate antigen 19-9; Carbohydrate antigen 72-4 |
| Core Tip |
This study demonstrated that sintilimab plus S-1 plus oxaliplatin/xeloda plus oxaliplatin regimen therapy significantly enhanced the reduction in tumor markers and improved tumor marker response rates in patients with advanced gastric cancer. The early and profound decrease in these markers showed a significant positive correlation with objective tumor shrinkage, highlighting their potential as valuable dynamic indicators for evaluating the efficacy of this immunochemotherapy combination. |
| Publish Date |
2026-05-14 09:17 |
| Citation |
Quan HL, Xia L, Hu Y, Wang GY, Wang C. Impact of sintilimab with first-line therapy on tumor marker response in advanced gastric cancer. World J Gastrointest Oncol 2026; 18(5): 117085 |
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i5/117085.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v18.i5.117085 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
